Enclomiphene – 12.5mg

(Selective Estrogen Receptor Modulator – SERM)

Enclomiphene is a nonsteroidal selective estrogen receptor modulator (SERM) and the trans-isomer of clomiphene citrate. It acts primarily as an estrogen receptor antagonist in the hypothalamus and pituitary gland, blocking estrogen-mediated negative feedback. This results in increased gonadotropin-releasing hormone (GnRH) secretion, elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and subsequent stimulation of endogenous testosterone production in research models.

Enclomiphene has been investigated as a potential alternative to testosterone replacement therapy, with studies focusing on its ability to restore and maintain physiological testosterone levels while preserving fertility.

Mechanism of Action (Based on Preclinical and Clinical Research):

• Antagonizes estrogen receptors in the hypothalamus and pituitary

• Increases GnRH release, stimulating LH and FSH secretion

• Enhances endogenous testosterone production while maintaining spermatogenesis

• Functions as a SERM with tissue-selective activity (antagonist in the hypothalamus, partial agonist elsewhere)

Potential Benefits (Based on Preclinical Research):

• Studied for boosting endogenous testosterone without suppressing fertility

• Explored as an alternative to exogenous testosterone therapy in male models

• Potential benefits for maintaining sperm count and reproductive function

• Investigated for modulation of estrogen-sensitive pathways with reduced risk of feminizing effects compared to clomiphene mixtures

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

Enclomiphene – 12.5mg

(Selective Estrogen Receptor Modulator – SERM)

Enclomiphene is a nonsteroidal selective estrogen receptor modulator (SERM) and the trans-isomer of clomiphene citrate. It acts primarily as an estrogen receptor antagonist in the hypothalamus and pituitary gland, blocking estrogen-mediated negative feedback. This results in increased gonadotropin-releasing hormone (GnRH) secretion, elevated luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and subsequent stimulation of endogenous testosterone production in research models.

Enclomiphene has been investigated as a potential alternative to testosterone replacement therapy, with studies focusing on its ability to restore and maintain physiological testosterone levels while preserving fertility.

Mechanism of Action (Based on Preclinical and Clinical Research):

• Antagonizes estrogen receptors in the hypothalamus and pituitary

• Increases GnRH release, stimulating LH and FSH secretion

• Enhances endogenous testosterone production while maintaining spermatogenesis

• Functions as a SERM with tissue-selective activity (antagonist in the hypothalamus, partial agonist elsewhere)

Potential Benefits (Based on Preclinical Research):

• Studied for boosting endogenous testosterone without suppressing fertility

• Explored as an alternative to exogenous testosterone therapy in male models

• Potential benefits for maintaining sperm count and reproductive function

• Investigated for modulation of estrogen-sensitive pathways with reduced risk of feminizing effects compared to clomiphene mixtures

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

SLU-PP-332 – 500mcg

(PPARδ/PPARβ Modulator – Experimental Small Molecule)

SLU-PP-332 is an experimental small molecule investigated as a selective modulator of peroxisome proliferator-activated receptor delta/beta (PPARδ/β). PPARδ is a nuclear receptor that regulates genes involved in fatty acid oxidation, glucose metabolism, mitochondrial biogenesis, and endurance adaptations. By modulating PPARδ activity, SLU-PP-332 has been studied in preclinical settings for its role in energy homeostasis, exercise-mimetic pathways, and potential therapeutic exploration in metabolic disorders.

Mechanism of Action (Based on Preclinical Research):

• Selectively binds and activates PPARδ/β nuclear receptors

• Upregulates genes associated with fatty acid transport and oxidation

• Promotes mitochondrial biogenesis and oxidative muscle fiber adaptation

• Enhances endurance-like metabolic signatures without direct exercise stimulus

Potential Benefits (Based on Preclinical Research):

• Studied for improvements in lipid metabolism and fatty acid oxidation

• Investigated for enhanced endurance and exercise-mimetic effects in animal models

• Potential applications in obesity, insulin resistance, and metabolic disease research

• Explored for mitochondrial support and cellular energy regulation

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.